Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 6/20 | 0.38 |
| ▸ | GSPT1 | P15170 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.37 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25899542 | 0.88 | CRBN (0.41) | CRBNDDB1GSPT1IKZF3 | |
| SCHEMBL21760038 | 0.88 | CRBN (0.44) | CRBNDDB1 | |
| SCHEMBL22733426 | 0.86 | CRBN (0.44) | CRBNDDB1IKZF3IKZF1 | |
| SCHEMBL22661403 | 0.84 | CRBN (0.42) | CRBNDDB1IKZF1 | |
| SCHEMBL23140136 | 0.84 | CRBN (0.42) | CRBNDDB1IKZF1 | |
| SCHEMBL25900179 | 0.82 | CRBN (0.48) | CRBNDDB1GSPT1CYP2C19KCNH2 | |
| SCHEMBL22512216 | 0.82 | CRBN (0.57) | CRBNDDB1IKZF3IKZF1 | |
| SCHEMBL24294674 | 0.82 | CRBN (0.45) | CRBNDDB1IKZF3 | |
| SCHEMBL20323937 | 0.82 | CRBN (0.45) | CRBNDDB1IKZF3 | |
| SCHEMBL25771919 | 0.81 | CRBN (0.46) | CRBNDDB1IKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230248833-A1 | COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230248833-A1 | COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR | BTK, WEE1, WEE2 | CRBN 2529/4885DDB1 3863/4885GSPT1 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.